Portfolio Lab

Recursion Pharmaceuticals, Inc.

  • Stock
  • Ticker RXRX
  • Nasdaq

Health care · Biotechnology · USA

$2.45 −9.93%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Recursion Pharmaceuticals, Inc. since 04/2021, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

RXRXGlobal equities (VT)

$10,000 grew to $1,279. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −94.1% in 11/2026, measured from the peak in 07/2021. The old peak has not been reached again yet.

1-year return
−36.4%
5-year return p.a.
−34.2%
Return p.a. since 04/2021
−36.6%
Volatility p.a.
84.5%
Largest decline
−94.1%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue4.515195.2366.57.719
Gross profit-8.2-7.1-0.9-9.521-6.0-3.88.5
Operating income-184-191-176-172-108-129-135-123
EBITDA-171-172-152-151-89-109-117-107
Net income-179-202-172-162-108-118-131-119
Earnings per share-0.57-0.50-0.41-0.36-0.17-0.22-0.25-0.22
Balance sheet
Total assets1,4491,3051,3021,4001,4741,3401,2131,222
Liabilities414371383353343315298316
Equity1,0359349191,0471,1311,025915906
Cash594500525660743654546550
Cash flow
Operating cash flow-115-132-76-117-46-81-106-77
Capital expenditure-1.3-1.8-3.2-0.2-1.2-0.30.0-0.4
Free cash flow-117-134-80-118-47-81-106-78

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2023 at +27.9%, weakest 2022 at −55.0%. 1 of 4 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
2 Nov 2026−$0.22
5 Aug 2026−$0.25
6 May 2026−$0.22
25 Feb 2026−$0.17
5 Nov 2025−$0.36
5 Aug 2025−$0.41
5 May 2025−$0.50
28 Feb 2025−$0.57
6 Nov 2024−$0.34
8 Aug 2024−$0.40
9 May 2024−$0.39
29 Feb 2024−$0.42

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€1.4bn
Market cap in trading currency
$1.53bn
Enterprise value
$976m
P/E
–
P/S
22.36
P/B
1.68
EV/Sales
14.30
EV/EBITDA
–
Earnings yield
–
FCF yield
-20.5%

Results (last four quarters)

Revenue
$68.2m
Gross profit
$19.9m
EBITDA
−$421m
Net income
−$476m
Earnings per share
−$0.86
Revenue per share
$0.11
Revenue growth
+258.5%
Earnings growth
–

Profitability

Gross margin
29.2%
Operating margin
-725.4%
Net margin
-697.1%
Return on equity
-48.7%
Return on assets
-38.9%

Balance sheet and cash flow

Cash
$550m
Cash per share
$0.88
Financial debt
–
Debt/equity %
–
Current ratio
5.01
Book value per share
$1.45
Operating cash flow
−$311m
Free cash flow
−$312m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
623m
Volume
29.7m
Avg. volume 3 months
23.4m
Relative volume
1.2

Price and technicals

Price
$2.45
1 day
−9.9%
52-week high
$4.96
52-week low
$2.45
Distance to 52-week high
−50.6%
Distance to 52-week low
0.0%
Distance to 50-day line
−34.1%
Distance to 200-day line
−28.9%
RSI (14)
31
Volatility 1M
94.1%

Performance

1 week
−23.1%
1 month
−31.6%
3 months
−24.6%
6 months
−18.6%
YTD
−40.1%
1 year
−39.2%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has RXRX performed since 04/2021?

$10,000 grew to $783 by 20 Nov 2026, which is −36.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is RXRX?

Volatility was 84.5% per year, measured on monthly returns. The largest decline from a peak was −94.1%, with the low in 11/2026.

How does RXRX compare with a broad equity ETF?

Over the same period Global equities (VT) returned +8.2% per year at 14.9% volatility, RXRX returned −36.6% at 84.5%. The correlation of monthly returns was 0.22; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Recursion Pharmaceuticals, Inc. (RXRX): Return and risk